Assesses HRD status quantification in ovarian cancer, indicating relevance for treatment decisions.
Homologous Recombination Deficiency (HRD) is a complex biomarker and directly impacts treatment decision-making in ovarian cancer (OC). Tumors harboring BRCA1 and/or BRCA2 mutations or HRD positive tumors are eligible for poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy. In Denmark, all patients diagnosed with high-grade OC (FIGO stage III or IV) or platinum-sensitive relapsed OC can be offered PARPi maintenance therapy. In this study we assessed the concordance between three methods for quantifying HRD status in OC patients.
No takes yet. Share an insight, caveat, or question.
Madsen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: